Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium (177Lu) rosopatamab tetraxetan + docetaxel
- Development stage
- Phase 3
- Lead developer
- Telix Pharmaceuticals
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a **combination drug** consisting of **lutetium (177Lu) rosopatamab tetraxetan** and **docetaxel**. Lutetium (177Lu) rosopatamab tetraxetan is a radio-antibody-drug conjugate (rADC) comprised of the therapeutic isotope lutetium-177 attached to the monoclonal antibody rosopatamab, which targets the **prostate-specific membrane antigen (PSMA)** expressed on prostate cancer cells[1][6][8]. When administered, the antibody binds PSMA on tumor cells, delivering local beta radiation that causes DNA damage and tumor cell death while minimizing harm to adjacent healthy tissue[5][6][8]. Docetaxel is a chemotherapy agent that stabilizes microtubules, disrupting cell division. The combination is under investigation for **PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)** after androgen receptor pathway inhibitor therapy[1][3][7]. This therapeutic approach is being evaluated for synergistic efficacy, leveraging both targeted radiotherapy and cytotoxic chemotherapy.
- Other names
- lutetium (177Lu) rosopatamab tetraxetan + docetaxel
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on lutetium (177Lu) rosopatamab tetraxetan + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium (177Lu) rosopatamab tetraxetan + docetaxel.